Forward-Looking Statements Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect Anixa's current expectations concerning future events and results. We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify forward-looking statements. Such ...

Group 1 - Anixa Biosciences, Inc. is participating in the H.C. Wainwright 3rd Annual BioConnect Investor Conference on May 20, 2025, at Nasdaq World Headquarters in New York City [1][2] - Mike Catelani, President and CFO of Anixa, will present and be available for one-on-one meetings during the conference [1][2] - Anixa is a clinical-stage biotechnology company focused on cancer treatment and prevention, with a therapeutic portfolio that includes an ovarian cancer immunotherapy program developed in collaboration with Moffitt Cancer Center [2] Group 2 - The company's vaccine portfolio includes vaccines for breast and ovarian cancer developed in collaboration with Cleveland Clinic, as well as additional vaccines targeting high incidence malignancies in lung, colon, and prostate cancers [2] - Anixa's business model involves partnerships with renowned research institutions at all stages of development, allowing for the exploration of emerging technologies for further development and commercialization [2]

Core Viewpoint - Anixa Biosciences (ANIX) shares rose by 13% following the announcement of a new patent for its breast cancer vaccine technology, developed in collaboration with Cleveland Clinic, which is currently in early-stage studies [1][4]. Group 1: Patent and Technology - The new patent broadens the immunogenic compositions for Anixa's breast cancer vaccine, focusing on the human α-lactalbumin protein, which is present in breast tissue during lactation and expressed in certain breast cancers, making it a viable target for immunoprevention [2]. - The patent enhances Anixa's intellectual property portfolio, emphasizing the uniqueness of its investigational breast cancer vaccine, thereby strengthening the company's competitive position [4]. Group 2: Clinical Trials and Future Plans - The ongoing phase I study is assessing the breast cancer vaccine's maximum tolerated dose and immune response in patients with early-stage, triple-negative breast cancer, showing antigen-specific immune responses and a favorable safety profile [5]. - Based on positive findings, Anixa plans to initiate a phase II study in 2025 to evaluate the vaccine's therapeutic effect in a pre-surgery setting for breast cancer [5]. Group 3: Collaborations and Other Developments - Anixa is collaborating with Cleveland Clinic on additional vaccines targeting ovarian, lung, colon, and prostate cancers, which are currently in pre-clinical or discovery stages [7]. - The innovative vaccine technologies have a unique mechanism of action, potentially offering therapeutic benefits over existing treatments, with Cleveland Clinic entitled to royalties from their development [8]. - Anixa is also developing an immunotherapy candidate for ovarian cancer in partnership with Moffitt Cancer Center, currently in a phase I study [9].

Core Points - Anixa Biosciences has received a Notice of Allowance for a new patent related to its breast cancer vaccine technology, which broadens the scope of immunogenic compositions used in the vaccine [1][2] - The patent covers methods of immunizing patients against breast cancer using an immunogenic composition containing the human α-lactalbumin protein, which is expressed in certain breast cancers [2] - The CEO of Anixa highlighted that this patent enhances the company's intellectual property portfolio, which includes multiple issued and pending patents in the U.S. and internationally [3] Company Overview - Anixa Biosciences is a clinical-stage biotechnology company focused on cancer treatment and prevention, with a therapeutic portfolio that includes an ovarian cancer immunotherapy program developed in collaboration with Moffitt Cancer Center [3] - The company's vaccine portfolio includes vaccines for breast and ovarian cancer, as well as other cancer vaccines targeting high incidence malignancies such as lung, colon, and prostate cancers [3] - Anixa's business model involves partnerships with renowned research institutions, allowing the company to explore emerging technologies for further development and commercialization [3]

Core Viewpoint - Anixa Biosciences, Inc. is participating in the Jones Las Vegas Healthcare and Technology Innovation Conference, highlighting its focus on cancer treatment and prevention [1][2]. Group 1: Conference Details - The conference will take place on April 8-9, 2025, at The Venetian Resort in Las Vegas, Nevada [1]. - Mike Catelani, President and CFO of Anixa, will present on April 9, 2025, at 4:30 PM PT and will be available for one-on-one meetings [2]. - The event aims to facilitate direct dialogue between innovative companies and institutional investors through various formats including presentations and networking events [2]. Group 2: Company Overview - Anixa is a clinical-stage biotechnology company focused on cancer treatment and prevention, with a therapeutic portfolio that includes an ovarian cancer immunotherapy program developed in collaboration with Moffitt Cancer Center [4]. - The company is also developing vaccines in partnership with Cleveland Clinic to treat and prevent breast and ovarian cancers, as well as other vaccines targeting high incidence malignancies such as lung, colon, and prostate cancers [4]. - Anixa's business model involves partnerships with renowned research institutions, allowing for continuous exploration of emerging technologies for development and commercialization [4].

Core Viewpoint - Anixa Biosciences has entered into a letter of intent with VERDI Solutions to develop personalized and off-the-shelf peptide vaccines for cancer patients, leveraging advanced technology and real-world data to enhance treatment accessibility and efficacy [1][5]. Group 1: Company Overview - Anixa Biosciences is a clinical-stage biotechnology company focused on cancer treatment and prevention, with a portfolio that includes immunotherapy programs and various cancer vaccines developed in collaboration with renowned research institutions [8][9]. - VERDI Solutions, based in Vienna, Austria, is pioneering personalized cancer treatment by utilizing artificial intelligence and cloud computing to create tailored cancer vaccines, making them more accessible to patients [2]. Group 2: Technology and Innovation - VERDI's cloud-computing platform allows for rapid development of personalized peptide vaccines based on individual patient data, aiming to improve treatment outcomes through companion diagnostics [2][6]. - The company has successfully administered personalized vaccines to three patients with bone metastases, resulting in significant pain relief and improved quality of life, indicating the potential of its platform [4][6]. Group 3: Regulatory and Market Context - In some European countries, oncologists can prescribe personalized cancer vaccines under the Individueller Heilversuch, providing a pathway for broader patient access and valuable real-world efficacy data [3]. - The increasing recognition of real-world evidence by global regulatory agencies supports the development and commercialization of personalized cancer vaccines, positioning VERDI as a leader in this innovative approach [3]. Group 4: Strategic Collaboration - The letter of intent grants Anixa a six-month exclusive right to negotiate for the research, development, and commercialization of VERDI's cancer vaccines, aligning with Anixa's strategy for a capital-efficient business model in personalized cancer care [5][7].

Core Insights - Anixa Biosciences has received a Notice of Allowance from the USPTO for a key patent application related to its ovarian cancer vaccine technology, which targets Anti-Mullerian Hormone Receptor, Type II (AMHR2) [1][4] - The ovarian cancer vaccine is being developed in collaboration with Cleveland Clinic and the National Cancer Institute, focusing on high-risk populations such as those with BRCA mutations [2] - The allowed claims cover methods of administering an immunogenic composition that elicits an AMHR2-specific immune response [3] Company Overview - Anixa is a clinical-stage biotechnology company dedicated to cancer treatment and prevention, with a focus on ovarian cancer immunotherapy and a unique CAR-T technology [4] - The company collaborates with renowned research institutions to develop vaccines for various cancers, including breast, lung, colon, and prostate cancers, targeting "retired" proteins expressed in these malignancies [4] - Anixa's business model emphasizes partnerships at all stages of development, allowing for the exploration of emerging technologies for commercialization [4]

Core Insights - Anixa Biosciences, Inc. is set to present at the 2025 Cancer Advocacy Group of Louisiana NeauxCancer Conference, highlighting its advancements in cancer treatment and prevention [1][2] - The presentation will focus on Anixa's CAR-T therapy for solid tumors and novel cancer vaccine initiatives, showcasing the company's progress in clinical development and next-generation immunotherapies [2] Company Overview - Anixa is a clinical-stage biotechnology company dedicated to cancer treatment and prevention, with a therapeutic portfolio that includes an ovarian cancer immunotherapy program developed in collaboration with Moffitt Cancer Center [4] - The company is also developing vaccines in partnership with Cleveland Clinic to treat and prevent breast and ovarian cancers, as well as other vaccines targeting high incidence malignancies such as lung, colon, and prostate cancers [4] - Anixa's business model involves collaboration with renowned research institutions throughout all stages of development, allowing for the exploration of emerging technologies for further development and commercialization [4]

Revenue Performance - Revenue for the three months ended January 31, 2025, was $0, consistent with the same period in 2024[81]. - The company does not expect to begin generating revenue from its current therapy or vaccine programs in the near term[82]. Expenses - Research and development expenses increased by approximately $203,000 to approximately $1,552,000 for the three months ended January 31, 2025, compared to approximately $1,349,000 in the same period in 2024[84]. - General and administrative expenses decreased by approximately $426,000 to approximately $1,834,000 for the three months ended January 31, 2025, from approximately $2,260,000 in the same period in 2024[86]. - Interest income decreased by approximately $146,000 to approximately $173,000 for the three months ended January 31, 2025, from approximately $319,000 in the same period in 2024[87]. Assets and Cash Flow - Total current assets decreased by approximately $2,676,000 to approximately $18,686,000 as of January 31, 2025, compared to approximately $21,362,000 at October 31, 2024[90]. - Cash used in operating activities was approximately $2,904,000 for the three months ended January 31, 2025[91]. - Cash provided by investing activities was approximately $2,703,000, resulting from the maturities of short-term investments of approximately $15,700,000[91]. - The company has approximately $97 million of common stock available for sale under its at-the-market equity program as of January 31, 2025[90]. Net Loss - The net loss attributable to noncontrolling interest decreased by approximately $6,000 to approximately $29,000 for the three months ended January 31, 2025[88].

Company Overview - Anixa Biosciences, Inc. is a clinical-stage biotechnology company focused on cancer treatment and prevention [3] - The company has a therapeutic portfolio that includes an ovarian cancer immunotherapy program developed in collaboration with Moffitt Cancer Center, utilizing chimeric endocrine receptor-T cell (CER-T) technology [3] - Anixa's vaccine portfolio includes vaccines for breast and ovarian cancer, developed in collaboration with Cleveland Clinic, as well as additional vaccines targeting high incidence malignancies such as lung, colon, and prostate cancers [3] - The company partners with renowned research institutions to explore emerging technologies for further development and commercialization [3] Upcoming Events - Anixa will host its 2025 Annual Meeting of Stockholders on March 20, 2025, at 10:00 a.m. Pacific Time in a virtual format [1] - Following the formal business and voting portion, Anixa's Chairman and CEO, Dr. Amit Kumar, will deliver an investor presentation and corporate update, followed by a Q&A session [2] - Interested parties can access the meeting online at www.virtualshareholdermeeting.com/ANIX2025 [2]